Calgene, Inc. Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Research and Development (R&D) Spending: Calgene spent $15.4M in 1991, up from $12.3M in 1990 (Exhibit 1).
Net Loss: $10.6M in 1991, compared to $9.3M in 1990 (Exhibit 1).
Cash Position: $13.5M in cash and equivalents as of June 1991 (Exhibit 2).
Burn Rate: Operating losses averaged roughly $0.8M to $1M per month during the 1991 fiscal year.

Operational Facts

Primary Product: Flavr Savr tomato (genetically engineered for delayed ripening).
Regulatory Status: FDA approval process for the Flavr Savr is the critical bottleneck (Paragraph 14).
Business Model: Calgene intends to produce and market the tomato itself rather than just licensing the technology (Paragraph 22).

Stakeholder Positions

Roger Salquist (CEO): Believes in vertical integration to capture full value of the technology; views the FDA approval as a technical rather than political hurdle.
Investors: Concerned about the extended timeline to profitability and the capital intensity of scaling tomato production.

Information Gaps

Consumer demand elasticity for a premium-priced tomato is untested.
Scalability of proprietary distribution channels remains unproven.
Exact date for FDA approval remains speculative.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Can Calgene sustain its cash burn long enough to commercialize the Flavr Savr via a direct-to-market model, or must it pivot to a licensing strategy to survive?

Structural Analysis

Value Chain: Calgene is attempting to control the entire chain from gene discovery to retail distribution. This creates extreme capital requirements and operational complexity for a firm with limited cash.
Regulatory Environment: The FDA is the ultimate gatekeeper. The strategy relies on an assumption of favorable regulatory treatment that is currently outside the company control.

Strategic Options

Option 1: Vertical Integration. Proceed with proprietary production and distribution. Trade-off: High potential margin but high capital risk. Requirement: Immediate secondary equity offering.
Option 2: Licensing Model. Partner with established produce distributors (e.g., Dole, Chiquita). Trade-off: Lower margins, loss of long-term brand control. Requirement: Negotiating power shift from technical capability to commercial readiness.
Option 3: Hybrid Approach. License the technology for bulk processing while maintaining control of the fresh-market brand. Trade-off: Complexity in managing two distinct business models.

Preliminary Recommendation

Pursue Option 2. The current cash position of $13.5M is insufficient to fund both the remaining R&D and the capital-intensive infrastructure required to disrupt the tomato supply chain.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Initiate discussions with Tier-1 produce distributors within 30 days to secure a letter of intent.
Halt capital expenditure on internal distribution infrastructure to preserve remaining cash.
Finalize regulatory dossier for the FDA to expedite the approval process.

Key Constraints

Cash Runway: With a $1M monthly burn, the company has roughly 12-14 months before insolvency.
Regulatory Uncertainty: Any delay in FDA approval renders the commercialization plan moot.

Risk-Adjusted Implementation

Maintain a lean core team focused strictly on regulatory compliance.
Outsource all non-essential logistics to partners to minimize fixed asset investment.

4. Executive Review and BLUF (Executive Critic)

BLUF

Calgene is a technology company attempting to become a produce company. This is a fundamental strategic error. The firm lacks the capital, infrastructure, and market access to compete with established distributors. Continuing the current path of vertical integration will lead to insolvency before the Flavr Savr reaches meaningful scale. Calgene must pivot immediately to a pure-play licensing model. This preserves the remaining $13.5M in cash, shifts the capital burden to partners with existing distribution networks, and refocuses the firm on its true competency: agricultural biotechnology. The current strategy is a vanity project that confuses technical success with commercial viability.

Dangerous Assumption

The assumption that a biotech firm can successfully enter the highly consolidated and low-margin produce distribution industry without incurring massive losses.

Unaddressed Risks

Regulatory Rejection: If the FDA requires additional, long-term testing, the company will run out of cash.
Consumer Backlash: Public perception of genetically modified foods could destroy the market before it begins.

Unconsidered Alternative

A strategic sale of the company to a major food conglomerate (e.g., Campbell Soup or similar) that possesses the capital to weather regulatory delays and the infrastructure to scale distribution.